Tempus AI, Inc.has announced a groundbreaking collaboration with biotechnology giant United Therapeutics (UT) to develop AI-powered medical software for early detection of pulmonary hypertension (PH).
The partnership aims to address the critical issue of delayed diagnosis in PH, a fatal and progressive heart and lung disease affecting approximately 1% of the population. Despite available treatments, PH diagnosis is often delayed by two or more years.
Tempus has developed an algorithm that analyzes 12-lead electrocardiogram (ECG) results to identify patients at risk of undiagnosed PH. The
